From Target to Clinical Candidate

Human Antibody
Discovery & Engineering

We turn your target innovation into therapeutic antibody candidates through our expertise and fully integrated R&D platform.

With decades of groundbreaking scientific expertise and an industry-proven track record, we support clients and partners from target validation and early antibody discovery through advanced engineering and lead optimization, delivering antibodies designed for potency, stability, safety, and pharma-ready manufacturability.

The Integrated YUMAB Platform

Flexible and Tailored from First Concept to
Optimized Therapeutic Antibodies

YUMAB supports your biotherapeutic development at every stage, from concept to lead optimization, with a comprehensive and flexible portfolio of services and technologies. From initial molecule generation and expert antibody engineering to CMC optimization, we combine scientific excellence, advanced technologies, and a collaborative approach to efficiently advance your drug candidate toward clinical success.

Antibody
Libraries

Fully human antibody library (scFv and Fab format) and customized immune libraries (scFv, Fab, VHH and paired libraries) generated from different species.
READ MORE

Antibody
Discovery

Antibody Discovery to all types of antigens: proteins, peptides, cells, haptens and difficult to access antigens (GPCR, channels).
READ MORE

Antibody
Development

Comprehensive biochemical and functional characterization of therapeutic lead candidates, including assay development.
READ MORE

Antibody
Engineering

Advancing suboptimal therapeutic leads into optimized drug candidates through AI-supported engineering.
READ MORE

Antibody
Humanization

Converting non-human-derived antibodies into fully humanized therapeutic candidates
READ MORE

Animal
health

Fully feline and canine antibody discovery and development platform.
READ MORE
Discuss your antibody program
multi-y-trenner-01
“Our partnership with YUMAB has been built on trust, collaboration, and a shared commitment to innovation in antibody discovery“ Dr. Cristina Pelizon, Senior Associate, Program Manager, Sofinnova Partners
“Yumab is a highly skilled and reliable partner for Tacalyx in the discovery of novel antibodies, with particular strength in advanced technologies such as the generation of paired H+L immune libraries that significantly improve the recovery of fully functional monoclonal antibodies.“ Dr. Peter Sondermann, CSO, Tacalyx GmbH
“We worked closely with Yumab during the development of our technology and pipeline assets. Both the scientific and the business teams at Yumab have been a joy to work with and have delivered excellent results.” Dr. Can Sönmezer, Founder & CEO, Kedi Bioscience B.V.
“With their expertise and technological capabilities, team YUMAB has been the right match for the successful development of Ent001. Always tuned to our needs they guided us through the process, saving time and clearing the path for a first-in-class IBD drug candidate.“ Dr. Virna Marin, Senior Project Manager R&D, Enthera Srl
“Big thanks for the seamless collaboration and the comprehensive 'Literature Digest' on our technology!“ Dr. Hendrik Schneider, Senior Scientist, Merck Group
“Our collaboration with YUMAB is defined by focus, flexibility, and outstanding scientific dialogue. Their dedication to our goals have been key enablers for Pexxes’ growth and development as a biotech.” Dr. Katharina Böhme, Co-Founder & CEO, Pexxes GmbH
“We have worked with Yumab on multiple antibody discovery projects. We have been impressed every time with the quality of the science and the antibodies delivered.” Dr. Ralph Minter, CTO, Forth Therapeutics Ltd.
“Our collaboration with YUMAB GmbH is scientifically productive, response times are fast, and the overall interaction is straightforward. And: it’s fun!” Prof. Dr. Dr. h. c. Martin Lohse, CEO, ISAR Bioscience
multi-y-trenner-02

Events

Discover more events

Locations

YUMAB is headquartered in Braunschweig, Germany. Founded as a spin-off from the University of Braunschweig, the company remains located on the Braunschweig South Science Campus, an internationally renowned research hub that continues to foster innovation and scientific collaboration. In 2017, YUMAB established its U.S. subsidiary in Atlanta, Georgia, to strengthen its presence and better serve customers across North America.

YUMAB Inc.

YUMAB GmbH

Get an initial consultation